Lung Cancer

Lung Cancer

SAFFRON: Osimertinib Plus Savolitinib May Set a New Standard of Care for Advanced NSCLC After Progression on EGFR TKI

November 19 7 min read
Patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations and MET alterations whose disease progressed on osimertinib experienced statistically significant benefits in progression-free survival and overall survival from the addition of the MET tyrosine kinase inhibitor savolitinib to osimertinib vs platinum/pemetrexed in subsequent lines of treatment in the phase III SAFFRON trial.

Latest in Lung Cancer